Authors: Adachi, JD Saag, KG Delmas, PD Liberman, UA Emkey, RD Seeman, E Lane, NE Kaufman, JM Poubelle, PEE Hawkins, F Correa-Rotter, R Menkes, CJ Rodriguez-Portales, JA Schnitzer, TJ Block, JA Wing, J McIlwain, HH Westhovens, R Brown, J Melo-Gomes, JA Gruber, BL Yanover, MJ Leite, MOR Siminoski, KG Nevitt, MC Sharp, JT Malice, MP Dumortier, T Czachur, M Carofano, W Daifotis, A

Citation: Jd. Adachi et al., Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids - A randomized, double-blind, placebo-controlled extension trial, ARTH RHEUM, 44(1), 2001, pp. 202-211

Authors: Kress, BC Mizrahi, IA Armour, KW Marcus, R Emkey, RD Santora, AC

Citation: Bc. Kress et al., Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women, CLIN CHEM, 45(7), 1999, pp. 1009-1017

Authors: Cohen, S Levy, RM Keller, M Boling, E Emkey, RD Greenwald, M Zizic, TM Wallach, S Sewell, KL Lukert, BP Axelrod, DW Chines, AA

Citation: S. Cohen et al., Risedronate therapy prevents corticosteroid-induced bone loss - A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, ARTH RHEUM, 42(11), 1999, pp. 2309-2318